Abstract
The field of angiogenesis and its mediators in tumour tissue is gaining more and more interest because of their therapeutic implications to arrest progressive growth and metastasis. We examined the expression status of the proangiogenic vascular endothelial growth factor (VEGF) in tumour tissue and adjacent tumour-free tissue from renal cell carcinoma (RCC) as well as in cell cultures deriving from tumour tissue. Quantification of both secreted isoforms ot VEGF by competitive RT-PCR revealed a marked increase of VEGF message in tumours and especially in cell cultures from RCC. We found a significant correlation of VEGF expression and microvessel density which was investigated immunohistochemically. As further compared to other urological neoplasms we investigated for VEGF mediated vascularization, RCC is the most promising candidate for anti-angiogenic therapies.
MeSH terms
-
Carcinoma, Renal Cell / blood supply
-
Carcinoma, Renal Cell / genetics*
-
Carcinoma, Renal Cell / pathology
-
Carcinoma, Renal Cell / surgery
-
Endothelial Growth Factors / genetics*
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Kidney / cytology
-
Kidney / metabolism
-
Kidney / pathology
-
Kidney Neoplasms / blood supply
-
Kidney Neoplasms / genetics*
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / surgery
-
Lymphokines / genetics*
-
Microcirculation / pathology
-
Neoplasm Staging
-
Nephrectomy
-
RNA, Messenger / analysis
-
RNA, Messenger / genetics
-
Reverse Transcriptase Polymerase Chain Reaction / methods
-
Transcription, Genetic*
-
Tumor Cells, Cultured
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factors
Substances
-
Endothelial Growth Factors
-
Lymphokines
-
RNA, Messenger
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factors